Education
About Us
Working with TipRanks
Follow Us
BioMarin Pharmaceutical (BMRN)
NASDAQ:BMRN
Total Valuation
BioMarin Pharmaceutical has a market cap or net worth of $11.44B. The enterprise value is $12.43B.
Market Cap$11.44B
Enterprise Value$12.43B
Share Statistics
BioMarin Pharmaceutical has 191.75M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding191.75M
Owned by Insiders0.95%
Owned by Instutions0.42%
Financial Efficiency
BioMarin Pharmaceutical’s return on equity (ROE) is 0.08 and return on invested capital (ROIC) is 5.97%.
Return on Equity (ROE)7.54%
Return on Assets (ROA)6.11%
Return on Invested Capital (ROIC)5.97%
Return on Capital Employed (ROCE)7.59%
Revenue Per Employee$937,678.947
Profits Per Employee$140,414.145
Employee Count3,040
Asset Turnover0.41
Inventory Turnover0.47
Valuation Ratios
The current PE Ratio of BioMarin Pharmaceutical is 29.26. BioMarin Pharmaceutical’s PEG ratio is 0.21.
PE Ratio29.26
PS Ratio4.38
PB Ratio2.21
Price to Fair Value2.21
Price to FCF26.27
Price to Operating Cash Flow21.80
PEG Ratio0.21
Income Statement
In the last 12 months, BioMarin Pharmaceutical had revenue of $2.85B and earned $426.86M in profits. Earnings per share was $2.25.
Revenue$2.85B
Gross Profit$2.24B
Operating Income$460.62M
Pretax Income$541.76M
Net Income$426.86M
EBITDA650.53M
Earnings Per Share (EPS)2.25
Cash Flow
In the last 12 months, operating cash flow was $572.84M and capital expenditures -$97.42M, giving a free cash flow of $475.42M billion.
Operating Cash Flow$572.84M
Free Cash Flow$475.42M
Free Cash Flow per Share$2.48
Dividends & Yields
BioMarin Pharmaceutical pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield3.81%
Earnings Yield3.42%
Stock Price Statistics
Beta0.42
52-Week Price Change-33.95%
50-Day Moving Average67.24
200-Day Moving Average72.13
Relative Strength Index (RSI)38.68
Average Volume (3m)1.79M
Important Dates
BioMarin Pharmaceutical upcoming earnings date is Apr 23, 2025, After Close.
Last Earnings DateFeb 19, 2025
Next Earnings DateApr 23, 2025
Ex-Dividend Date―
Financial Position
BioMarin Pharmaceutical as a current ratio of 5.33, with Debt / Equity ratio of 0.11
Current Ratio5.33
Quick Ratio3.29
Debt to Market Cap0.05
Net Debt to EBITDA-0.52
Interest Coverage Ratio39.24
Taxes
In the past 12 months, BioMarin Pharmaceutical has paid $114.90M in taxes.
Income Tax$114.90M
Effective Tax Rate21.21%
Enterprise Valuation
BioMarin Pharmaceutical EV to EBITDA ratio is 18.68, with an EV/FCF ratio of 25.56.
EV to Sales4.26
EV to EBITDA18.68
EV to Free Cash Flow25.56
EV to Operating Cash Flow21.21
Balance Sheet
BioMarin Pharmaceutical has $1.14B in cash and marketable securities with $602.71M in debt, giving a net cash position of -$534.99M billion.
Cash & Marketable Securities$1.14B
Total Debt$602.71M
Net Cash-$534.99M
Net Cash Per Share-$2.79
Tangible Book Value Per Share$27.40
Margins
Gross margin is 79.67%, with operating margin of 16.97%, and net profit margin of 14.96%.
Gross Margin79.67%
Operating Margin16.97%
Pretax Margin18.98%
Net Profit Margin14.96%
EBITDA Margin22.79%
EBIT Margin19.42%
Analyst Forecast
The average price target for BioMarin Pharmaceutical is $97.58, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$97.58
Price Target Upside62.58%
Analyst ConsensusStrong Buy
Analyst Count21
Revenue Growth Forecast17.35%
EPS Growth Forecast151.40%